The FDA approved 23andMe's direct-to-consumer test for three BRCA gene mutations linked to breast cancer, but the agency warned that most other BRCA mutations associated with an elevated breast cancer risk are not covered by the test. "The test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk," the FDA's Donald St. Pierre said.
FDA approves DTC test for breast cancer risk, with caveats
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.